

WEEKLY DIGEST OF COVID-19 GUIDELINES

WHO

- (1/5) WHO's Strategic Advisory Group of Experts on Immunization (SAGE) [convenes](#) an extraordinary meeting. They are expected to release recommendations and specific policies for the Pfizer/BioNTech vaccine based on data regarding safety, efficacy, and quality.
- (1/4) Globally, confirmed cases of COVID-19 reach over 85 million.
- (1/3) India approves the use of the AstraZeneca/Oxford vaccine.
- (12/31) WHO [issues](#) emergency use validation for the Pfizer-BioNTech vaccine, helping countries expedite regulatory approval and subsequent administration of the vaccine. The WHO's Emergency Use Listing also allows UNICEF and the Pan American Health Organization to distribute to countries in need.

CDC

- [\(1/6\) Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020](#)
 - “During December 14–23, 2020, monitoring by the Vaccine Adverse Event Reporting System detected 21 cases of anaphylaxis after administration of a reported 1,893,360 first doses of the Pfizer-BioNTech COVID-19 vaccine (11.1 cases per million doses); 71% of these occurred within 15 minutes of vaccination.”
- (12/31/20) [COVID-19 Vaccines and Allergic Reactions](#)
 - Provides recommendations on what to do if you experience an allergic reaction after getting a COVID-19 vaccination. It also provides recommendations for people who have had allergic reactions to other vaccines and for those with other types of allergies.
- (12/29/20) [Vaccination Considerations for Persons with Underlying Medical Conditions](#)
 - Includes considerations for people with weakened immune systems, autoimmune conditions, or history of Guillain-Barre or Bell's Palsy
- (12/28/20) Updated [Different COVID-19 Vaccines](#)
- (12/30/20) [Information for Pediatric Healthcare Providers](#)
 - This guidance is intended to inform pediatric healthcare providers of up-to-date information about children with suspected or confirmed COVID-19 and about caring for children during the pandemic.
- (1/3) [Emerging SARS-CoV-2 Variants](#), including why strain surveillance is important for public health.
- (12/29/20) [Interim: Implications of the Emerging SARS-CoV-2 Variant VOC 202012/01](#)
- (1/1) [Information about the Moderna COVID-19 Vaccine](#)
- (1/1) [Information about the Pfizer-BioNTech COVID-19 Vaccine](#)

- (12/28/20) [Coronavirus Self-Checker](#); a tool to help you make decisions on when to seek testing and medical care. Health departments and healthcare systems can add the Coronavirus Self-Checker to their own websites.
- (1/1) [COVID-19 Stats: COVID-19 Incidence, by Age Group — United States, March 1–November 14, 2020](#)
- (12/29/20) [Toolkit for Healthcare Providers](#), including clinical and vaccine resources, guidance and planning documents, web resources, and FAQ.
- (12/31/20) [Updated When Vaccine is Limited, Who Gets Vaccinated First?](#)
Understanding Phases 1a, 1b, 1c. The recommendations were made with these goals in mind:
 - Decrease death and serious disease as much as possible.
 - Preserve functioning of society.
 - Reduce the extra burden COVID-19 is having on people already facing disparities.
- (12/29/20) Updated [People with Certain Medical Conditions](#).
 - Adults of any age with certain underlying medical conditions are at increased risk for severe illness from the virus that causes COVID-19. The below list of underlying medical conditions is not exhaustive and only includes conditions with sufficient evidence to draw conclusions
- (12/29/20) Updated [COVID-19 Vaccination](#) dashboard.
- (12/31/20) [Running Essential Errands](#)
- (12/30/20) Updated [Operating schools during COVID-19: CDC's Considerations](#)
- (12/28/20) [Social Media Toolkit: COVID-19 & Mental Health](#)
- (12/28/20) [Funeral Guidance for Individuals and Families](#)
- (12/29/20) [Science Briefs](#)

NIH

- [Clinical Spectrum of SARS-CoV-2 Infection](#): expanded description of persistent symptoms or organ dysfunction based on the current knowledge of lingering effects
- [Prevention and Prophylaxis of SARS-CoV-2 Infection](#): results from two randomized control trials on use of hydroxychloroquine as pre-exposure prophylaxis for healthcare workers exposed to COVID19
- [Antithrombotic Therapy in Patients with COVID-19](#): special considerations during pregnancy and lactation in patients with COVID-19
 - For pregnant patients hospitalized for severe COVID-19, prophylactic dose anticoagulation is recommended if there are no contraindications to its use
 - VTE prophylaxis after hospital discharge is not recommended for pregnant patients. Decisions to continue VTE prophylaxis in the pregnant or postpartum patient after discharge should be individualized, considering concomitant VTE risk factors

- Anticoagulation therapy should be managed in pregnant patients with COVID-19 in a similar way as in pregnant patients with other conditions that require anticoagulation in pregnancy

IDSA

- (12/02) [Version 3.5.1](#) of IDSA's COVID-19 guidelines has been released and includes a summary table of COVID-19 treatment guidelines. This updated version has received endorsement from the Pediatric Infectious Diseases Society.